Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.
Pulse oximeters’ inaccuracies in darker-skinned people require urgent action, AGs tell FDA
More than two dozen attorneys general are urging Food and Drug Administration officials to take urgent action to address disparities in how well pulse oximeters,